These data, together with the proven ability of this compound to cross the blood–brain barrier (BBB) (Geretto et al., 2018), suggest that Fraisinib can kill two birds with one stone: targeting the primary tumor and its metastases “in one shot.” Taken together, this work suggests that the inhibition of GARS1 expression and/or GARS1 enzymatic activity may be innovative molecular targets for cancer treatment. This evidence concerns the gene GARS1 and cancer.